Alnylam Pharmaceuticals, Inc. Income Statement

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2009 Dec2010 Dec2011 Dec2012 Dec2013 Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 140.24M100.04M82.76M66.72M47.17M50.56M41.10M89.91M74.91M219.75M492.85M844.29M1037.42M1828.29M2248.24M
Cost of Revenue 1.80M25.06M74.19M115.00M140.17M268.22M306.51M
Gross Profit 140.24M100.04M82.76M66.72M47.17M50.56M41.10M89.91M73.11M194.69M418.67M729.28M897.24M1560.08M1941.73M
Operating items
Research & Development 108.73M106.38M99.30M86.57M112.96M190.25M276.50M390.63M505.42M655.11M654.82M792.16M883.01M1004.41M1126.23M
Selling, General & Administrative 39.91M37.73M38.28M44.61M27.15M44.53M60.61M199.37M382.36M479.00M588.42M620.64M770.66M795.65M975.53M
Other Operating Expenses 65.00M220.77M20.56M25.06M78.05M140.14M168.82M310.41M323.37M
Operating Expenses 148.64M144.11M137.57M196.18M140.11M455.54M337.11M590.00M889.58M1159.18M1321.29M1552.94M1822.49M2110.47M2425.13M
Operating Income -48.11M-44.07M-54.82M-129.46M-92.94M-404.98M-296.01M-500.09M-814.67M-939.43M-828.44M-708.65M-785.07M-282.18M-176.88M
EBIT -48.11M-44.07M-54.82M-129.46M-92.94M-404.98M-296.01M-500.09M-814.67M-939.43M-828.44M-708.65M-785.07M-282.18M-176.88M
Non-operating items
Non Operating Investment Income 4.42M16.08M
Interest & Investment Income 5.38M2.31M1.21M0.98M1.07M2.56M5.86M12.24M29.26M33.45M11.81M1.58M24.81M95.56M121.99M
Other Non Operating Income 0.63M1.98M-0.53M0.33M-0.05M1.82M0.08M-3.02M24.74M20.73M57.33M-2.05M-134.18M-125.68M-180.62M
Non Operating Income 1.10M1.98M-2.83M12.87M1.02M4.38M5.93M9.21M54.00M54.18M57.33M-143.49M-341.92M-151.34M-200.49M
Net income details
EBT -47.01M-43.00M-57.65M-116.59M-91.92M-400.60M-290.07M-490.87M-760.67M-885.25M-855.60M-852.14M-1126.99M-433.52M-377.38M
Tax Provisions 0.58M0.57M0.05M-10.57M-2.69M0.82M0.86M2.68M0.68M4.16M6.72M-99.22M
Profit After Tax -66.39M-43.52M-57.65M-106.01M-89.22M-360.39M-290.07M-490.87M-761.50M-886.12M-858.28M-852.82M-1131.16M-440.24M-278.16M
Equity Income -4.91M-7.64M-3.50M-4.52M
Investment Income -0.12M
Income from Continuing Operations -47.59M-43.57M-57.70M-106.01M-89.22M-400.60M-290.07M-490.87M-761.50M-886.12M-858.28M-852.82M-1131.16M-440.24M-278.16M
Consolidated Net Income -47.59M-43.57M-57.70M-106.01M-89.22M-400.60M-290.07M-490.87M-761.50M-886.12M-858.28M-852.82M-1131.16M-440.24M-278.16M
Income towards Parent Company -47.59M-43.57M-57.70M-106.01M-89.22M-400.60M-290.07M-490.87M-761.50M-886.12M-858.28M-852.82M-1131.16M-440.24M-278.16M
Net Income towards Common Stockholders -47.59M-43.57M-57.70M-106.01M-89.22M-400.60M-290.07M-490.87M-761.50M-886.12M-858.28M-852.82M-1131.16M-440.24M-278.16M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 41.82M42.20M42.73M52.41M63.92M76.93M84.74M85.81M92.73M101.03M111.49M116.18M119.60M123.03M125.49M128.98M
Shares Outstanding (Diluted Average) 109.26M114.99M118.45M121.69M124.91M127.65M
EBITDA -48.06M-43.52M-58.53M-90.19M-85.17M-331.35M-334.47M-491.87M-760.28M-889.42M-865.38M-842.46M-1142.55M-418.96M-289.30M
Tax Rate 9.07%2.93%26.29%